Cerebrolysin Comparative Pharmacology — Research Reference
Cerebrolysin, a porcine-derived neuropeptide preparation, is primarily studied in neurotrophic research contexts for its multifaceted pharmacological profile, making it a subject of considerable interest for comparative analysis against other compounds in experimental settings. Its complex composition and proposed mechanisms, distinct from single-entity neurotrophic factors or synthetic compounds, position it uniquely within the landscape of neurobiological investigation.
As a neuropeptide preparation, Cerebrolysin has been the subject of numerous indexed publications on PubMed and several registered studies on ClinicalTrials.gov, reflecting a broad base of experimental inquiry into its potential influence on neuronal health, function, and repair mechanisms in various research models. This reference page serves exclusively for research purposes, providing a comparative overview of Cerebrolysin’s pharmacology within the bounds of scientific investigation and without endorsing or suggesting any application for human use.
Understanding Cerebrolysin: A Neuropeptide Preparation in Research
Cerebrolysin is classified within the domain of neuropeptide preparations, representing a complex mixture derived from porcine brain proteins through enzymatic hydrolysis. This intricate composition distinguishes it from isolated single-entity peptides, positioning it as a multi-component agent for neurotrophic research. Its fundamental utility in scientific investigation lies in its capacity to influence a broad spectrum of cellular and molecular processes pertinent to neural function and pathology in various experimental models. Researchers explore its potential to modulate cellular survival, synaptic plasticity, and neuronal repair mechanisms under controlled laboratory conditions, contributing to a deeper understanding of complex neurological pathways. The non-specific yet broad-acting nature of such preparations warrants meticulous control in research designs to precisely attribute observed effects to specific components or combined actions.
The research interest surrounding Cerebrolysin stems from its proposed neurotrophic properties, which have been a subject of extensive preclinical and some clinical investigational studies. As a porcine-derived preparation, its composition includes various biologically active peptides and amino acids, theorized to collectively exert neurotrophic, neuroprotective, and neuromodulatory effects within cellular and animal models. This multifaceted composition provides a rich canvas for researchers aiming to dissect the interplay of various peptide fractions and their combined impact on neural systems. Understanding the precise biochemical fingerprint of Cerebrolysin, as verified through Certificate of Analysis (CoA) and other analytical methods, is crucial for ensuring reproducibility and comparability across diverse research settings.
In the broader landscape of research peptides, Cerebrolysin stands out due to its unique origin and complex nature. Unlike synthetic, single-entity peptides designed for highly specific receptor interactions, Cerebrolysin’s activity is posited to arise from the synergistic effects of its various components. This complexity presents both challenges and opportunities for researchers. While isolating the contribution of individual components can be demanding, the preparation offers a holistic approach to investigating neurobiological phenomena. Its extensive history in research, evidenced by numerous publications indexed in PubMed and several registered studies on ClinicalTrials.gov, highlights a sustained scientific interest in its potential research applications and the continued effort to elucidate its mechanisms of action in controlled experimental environments. For further context on the diverse applications and types of such agents, researchers may consult resources detailing what are research peptides.
Pharmacological Mechanisms of Cerebrolysin: A Research Perspective
The proposed pharmacological mechanisms of Cerebrolysin in research models are multifaceted, reflecting its complex composition. Research suggests that it may exert its effects through several key pathways, primarily involving neurotrophic support, neuroprotection against various insults, and neuromodulation. Investigations in cellular and animal models indicate an influence on protein synthesis in neurons, potentially enhancing synaptic plasticity and overall neuronal health under stressed conditions. One significant hypothesis posits that Cerebrolysin mimics or enhances the activity of endogenous neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), without directly being these factors themselves. This indirect modulation of neurotrophic signaling pathways is a central area of ongoing research, aiming to understand how a complex peptide mixture can elicit such diverse biological responses.
Further research has explored Cerebrolysin’s potential impact on mitochondrial function and cellular energy metabolism within experimental paradigms. Studies utilizing in vitro models of neuronal injury, such as oxygen-glucose deprivation, have investigated whether Cerebrolysin can mitigate mitochondrial dysfunction, a critical factor in cellular demise during ischemic or excitotoxic events. By potentially stabilizing mitochondrial membranes, preserving ATP levels, and reducing the generation of reactive oxygen species, Cerebrolysin is hypothesized to enhance neuronal resilience. These lines of investigation are crucial for understanding its potential role in conditions where energy failure is a primary driver of neuropathology, always within the strict confines of research-use-only applications and without implying any human therapeutic claims.
The neuromodulatory aspects of Cerebrolysin are also a significant area of research interest. Experimental evidence suggests an influence on neurotransmitter systems, including glutamatergic, cholinergic, and GABAergic pathways. For instance, studies have explored its capacity to modulate glutamate excitotoxicity, a common mechanism of neuronal damage, by potentially influencing glutamate receptor function or uptake mechanisms. Similarly, its interaction with the cholinergic system, vital for cognitive functions in research models, is extensively investigated. These interactions underscore Cerebrolysin’s potential as a research tool for probing the intricate balance of neurotransmission and its disruption in experimental models of neurological dysfunction. Elucidating these intricate mechanisms forms a cornerstone of its comparative pharmacology and is essential for designing rigorous experimental protocols. More detailed information on these specific interactions can be found in dedicated resources on Cerebrolysin mechanism of action.
Moreover, investigations have focused on Cerebrolysin’s potential to influence gene expression profiles relevant to neuroplasticity and cellular repair. Research employing transcriptomic and proteomic approaches in cellular models has aimed to identify specific genes and proteins whose expression is altered following Cerebrolysin exposure. These studies seek to uncover the molecular cascades downstream of its initial interactions, providing a deeper understanding of its long-term effects on neuronal morphology, synapse formation, and dendritic arborization. Such insights are invaluable for researchers striving to build a comprehensive picture of how complex peptide preparations can impact the intricate machinery of the nervous system, guiding future research into targeted interventions.
Comparative Analysis with Other Neurotrophic Research Agents
When investigating neurotrophic research agents, it is crucial to perform comparative analyses to understand their unique properties, mechanisms, and potential applications within specific experimental models. Cerebrolysin, as a porcine-derived neuropeptide preparation, occupies a distinct position compared to single-entity recombinant neurotrophic factors like BDNF, NGF, or FGF-2, or synthetic small molecules designed to mimic neurotrophic activity. The primary distinction lies in its complex, multi-component nature versus the targeted action of purified proteins or synthetic compounds. This complexity means that Cerebrolysin’s effects are likely mediated by the synergistic actions of its various peptides and amino acids, potentially offering a broader spectrum of biological activities in certain research paradigms, but also posing challenges in isolating the precise contribution of individual components.
Research paradigms often compare Cerebrolysin’s neuroprotective efficacy against that of other agents in standardized injury models, such as glutamate excitotoxicity, oxidative stress, or oxygen-glucose deprivation in cellular cultures. For instance, while recombinant BDNF might activate specific TrkB signaling pathways, Cerebrolysin research suggests it may modulate the expression or activity of endogenous neurotrophic factors, thus potentially influencing multiple pathways indirectly. This distinction in mechanistic approach—direct activation versus indirect modulation—is critical for researchers designing studies to explore different facets of neuroprotection and neurorestoration. Understanding these nuances allows for a more informed selection of research tools based on the specific hypotheses being tested regarding cellular survival, axonal regeneration, or synaptic remodeling.
Furthermore, the bioavailability and pharmacokinetic profiles of Cerebrolysin in animal models present unique considerations compared to other research agents. Being a peptide mixture, its absorption, distribution, metabolism, and excretion in experimental animals are distinct from, for example, a lipid-soluble small molecule or a large protein that might be subject to rapid degradation or limited blood-brain barrier penetration. Researchers often need to account for these differences when determining dosing strategies and administration routes in their preclinical studies. The table below illustrates a conceptual comparison of Cerebrolysin with other classes of neurotrophic research agents based on typical research considerations.
| Research Agent Class | Composition Complexity | Proposed Mechanism of Action (Research) | Research Considerations (e.g., in vivo) |
|---|---|---|---|
| Cerebrolysin (Neuropeptide Preparation) | High (mixture of peptides/amino acids) | Modulation of endogenous neurotrophic factors, neuroprotection, neuromodulation, metabolic support | Broad-spectrum effects, potential for synergy, challenges in component attribution, specific ADME profile |
| Recombinant Neurotrophic Factors (e.g., BDNF) | Low (single protein) | Specific receptor activation (e.g., TrkB for BDNF), direct signaling cascade initiation | High specificity, potential for off-target effects at high doses, often poor BBB penetration, short half-life |
| Small Molecule Neurotrophic Mimetics | Low (single synthetic compound) | Targeted receptor binding or enzyme modulation, cell signaling pathway activation | Improved bioavailability, potential for specific targeting, often less complex effect profile, dose-dependent specificity |
| Exogenous Neuropeptides (e.g., VIP, PACAP) | Low (single peptide) | Specific G-protein coupled receptor activation, cAMP signaling, anti-inflammatory effects | Targeted effects, often short half-life, enzymatic degradation, diverse roles in neurobiology |
The choice between Cerebrolysin and other neurotrophic research agents ultimately depends on the specific objectives of a research study. If the goal is to investigate a broad-spectrum neuroprotective effect or to explore potential synergistic interactions among multiple neuroactive peptides, Cerebrolysin may offer a suitable model. Conversely, for studies focused on precisely dissecting a single signaling pathway or a specific receptor interaction, a purified recombinant factor or a targeted small molecule might be more appropriate. Rigorous experimental design, including appropriate controls and blinded assessments, remains paramount in comparative pharmacology studies to accurately interpret the observed outcomes and draw meaningful conclusions about the relative efficacy and mechanistic differences of these diverse agents in experimental settings.
Cerebrolysin and Cholinergic System Modulation Research
Research into Cerebrolysin’s influence on the cholinergic system is a significant area of investigation, particularly given the cholinergic system’s well-established role in cognitive functions, learning, and memory within experimental models. Studies have explored whether Cerebrolysin can modulate various aspects of cholinergic neurotransmission, including the synthesis, release, and metabolism of acetylcholine (ACh), as well as the integrity and function of cholinergic neurons. In several preclinical models of cognitive impairment, often induced by cholinergic denervation or neurotoxins, Cerebrolysin has been investigated for its potential to ameliorate deficits. These investigations typically involve assessing behavioral endpoints in animal models, alongside neurochemical and histological analyses of cholinergic markers in relevant brain regions.
One key hypothesis explored in research is Cerebrolysin’s potential to protect cholinergic neurons from damage and promote their survival in various insult models. For instance, in vitro studies using primary neuronal cultures exposed to neurotoxic agents have investigated whether Cerebrolysin can reduce apoptosis or improve cell viability among cholinergic populations. Furthermore, in vivo research in rodent models of neurodegeneration has examined its effects on cholinergic neuronal morphology, density, and enzyme activity, such as choline acetyltransferase (ChAT) and acetylcholinesterase (AChE). Alterations in these enzymes can significantly impact ACh levels and thus cholinergic signaling, making them critical targets for research into neuromodulatory compounds. Understanding how Cerebrolysin might influence the delicate balance of cholinergic function is essential for delineating its broader neurobiological research applications.
Beyond direct neuroprotection, research also investigates Cerebrolysin’s potential to influence synaptic plasticity within cholinergic pathways. This includes exploring its effects on the expression of cholinergic receptors (e.g., nicotinic and muscarinic receptors) and on the efficiency of synaptic transmission. Enhanced synaptic efficacy, potentially mediated by improved neurotransmitter release or receptor sensitivity, could underlie observed improvements in cognitive performance in animal models subjected to Cerebrolysin administration. These studies often employ electrophysiological techniques to measure synaptic potentials in brain slices or in vivo, providing dynamic insights into the functional consequences of Cerebrolysin’s interaction with the cholinergic system. The multi-component nature of Cerebrolysin suggests that its influence on cholinergic function may arise from a combination of direct and indirect mechanisms, warranting comprehensive analysis across multiple experimental levels.
The research interest in Cerebrolysin’s cholinergic modulation is further driven by its implications for understanding age-related cognitive decline and other neurological conditions where cholinergic deficits are prominent in experimental pathology. By elucidating the specific ways Cerebrolysin interacts with cholinergic neurons and their associated pathways, researchers aim to gain a deeper understanding of fundamental neurobiological processes. This includes exploring the interplay between Cerebrolysin’s proposed neurotrophic effects and its specific impact on the cholinergic system, investigating whether improvements in neuronal health generally translate to enhanced cholinergic function, or if there are more targeted interactions. Such detailed pharmacological profiling is critical for positioning Cerebrolysin as a valuable research tool for studying cholinergic system dynamics in experimental settings.
Investigating Cerebrolysin’s Influence on Excitotoxicity Models
Excitotoxicity, a pathological process where neurons are damaged and killed by excessive stimulation by excitatory neurotransmitters like glutamate, represents a critical mechanism in various acute and chronic neurological conditions in experimental models. Research into Cerebrolysin extensively explores its potential to mitigate excitotoxic damage in controlled laboratory settings. These investigations commonly employ both in vitro models, such as primary neuronal cultures exposed to supraphysiological concentrations of glutamate, NMDA, or kainate, and in vivo models, including global or focal cerebral ischemia, or direct intracerebral injections of excitotoxins in rodents. The objective is to determine if Cerebrolysin can improve neuronal survival, reduce cellular apoptosis, or preserve functional integrity in the face of such damaging stimuli.
The proposed mechanisms by which Cerebrolysin might exert its anti-excitotoxic effects are varied and are a focus of ongoing research. One hypothesis centers on its potential to modulate glutamate receptor activity or expression. Studies have investigated whether Cerebrolysin can directly or indirectly influence the function of NMDA or AMPA receptors, potentially reducing the excessive calcium influx that is characteristic of excitotoxic cascades. Another line of research explores its capacity to enhance glutamate reuptake mechanisms, primarily via glial transporters, thereby reducing extracellular glutamate concentrations and preventing sustained receptor overactivation. By contributing to the maintenance of glutamate homeostasis, Cerebrolysin is hypothesized to interrupt the feed-forward cycle of neuronal excitation and subsequent cell death in experimental paradigms.
Further investigations delve into Cerebrolysin’s role in bolstering intrinsic cellular defenses against excitotoxicity. This includes its potential influence on antioxidant pathways, mitochondrial stability, and the activation of pro-survival signaling cascades. Excitotoxicity is closely linked to oxidative stress and mitochondrial dysfunction; thus, research explores whether Cerebrolysin can reduce the generation of reactive oxygen species, maintain mitochondrial membrane potential, and prevent the release of pro-apoptotic factors from mitochondria. These multifaceted protective effects suggest that Cerebrolysin’s influence on excitotoxicity may not be limited to a single point of intervention but rather involves a systemic enhancement of neuronal resilience, making it a valuable agent for exploring complex neuroprotective strategies in research.
The rigorous design of experiments to study Cerebrolysin in excitotoxicity models is paramount. This includes dose-response studies in various models, careful selection of excitotoxic agents and concentrations, precise timing of Cerebrolysin administration relative to the insult, and the use of appropriate controls. Endpoint assessments range from cell viability assays and lactate dehydrogenase (LDH) release in cell cultures to infarct volume measurements, behavioral neurological scores, and histological analyses of neuronal loss in animal models. The consistent application of quality control measures for the Cerebrolysin preparation itself, as outlined in quality testing protocols, ensures that observed effects are attributable to the peptide mixture and not to impurities, thereby reinforcing the scientific validity and reproducibility of research findings in this critical area.
Research into Cerebrolysin’s Effects on Neuroinflammation
Neuroinflammation, characterized by the activation of glial cells (microglia and astrocytes) and the production of pro-inflammatory mediators within the central nervous system, is a fundamental component of various neurological disorders in experimental models. Research investigations into Cerebrolysin have extensively explored its potential to modulate inflammatory responses under conditions of acute injury and chronic neurodegeneration. These studies often employ in vitro models using primary glial cell cultures or immortalized microglial cell lines stimulated with lipopolysaccharide (LPS) or other inflammatory triggers, as well as in vivo models of inflammation, such as experimental autoimmune encephalomyelitis (EAE) or traumatic brain injury (TBI) in rodents. The goal is to ascertain whether Cerebrolysin can attenuate the inflammatory cascade and mitigate its deleterious effects on neuronal populations.
A primary focus of research is to determine if Cerebrolysin can influence the activation state of microglia, the resident immune cells of the brain. Microglia can adopt diverse phenotypes, ranging from pro-inflammatory (M1-like) to anti-inflammatory/pro-resolving (M2-like). Studies have investigated whether Cerebrolysin can shift microglial polarization towards a more protective M2-like phenotype, thereby reducing the release of destructive pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6, while potentially enhancing the production of anti-inflammatory cytokines like IL-10 or growth factors. Modulating this delicate balance in microglial activity is considered a promising strategy for neuroprotection in experimental contexts, and Cerebrolysin’s potential role in this process is a subject of active inquiry.
Furthermore, research has explored Cerebrolysin’s effects on astrocyte reactivity, another key player in neuroinflammation. Astrocytes, when activated, can contribute to both protective and detrimental responses, forming glial scars and altering metabolic support to neurons. Investigations seek to understand if Cerebrolysin can temper excessive astrocytic activation, reduce hypertrophic changes, and preserve the homeostatic functions of astrocytes in experimental models. This includes examining markers of astrogliosis, such as glial fibrillary acidic protein (GFAP) expression, and assessing the functional integrity of astrocyte-neuron interactions following inflammatory insults in the presence or absence of Cerebrolysin administration in research settings.
The multifaceted nature of neuroinflammation necessitates a comprehensive approach to studying Cerebrolysin’s impact. Researchers utilize a range of analytical techniques, including quantitative PCR, Western blotting, immunohistochemistry, and cytokine multiplex arrays, to measure changes in gene and protein expression related to inflammatory pathways. Functional assessments in animal models might include motor recovery, cognitive performance, and histological assessment of lesion volume and cellular infiltration. By elucidating how Cerebrolysin interacts with the complex machinery of neuroinflammation, researchers aim to gain a deeper understanding of its potential as a research tool for exploring strategies to mitigate inflammation-driven secondary damage in various experimental models, contributing to the broader field of neuroimmunology.
Cerebrolysin in Models of Cerebral Ischemia: A Research Focus
Cerebral ischemia, particularly stroke, is a devastating neurological condition, and research into neuroprotective and neurorestorative strategies forms a critical area of scientific inquiry. Cerebrolysin has been extensively investigated in various experimental models of cerebral ischemia, ranging from in vitro oxygen-glucose deprivation (OGD) in neuronal cell cultures to in vivo transient or permanent middle cerebral artery occlusion (MCAO) in rodents, which serve as common preclinical models for ischemic stroke. The primary objective of these studies is to evaluate Cerebrolysin’s potential to reduce ischemic injury, preserve neuronal viability, and improve functional outcomes in these highly relevant research paradigms.
A significant body of research focuses on Cerebrolysin’s neuroprotective efficacy when administered before or shortly after an ischemic event in animal models. Investigations typically assess critical endpoints such as infarct volume reduction using histological staining (e.g., TTC staining), evaluation of neuronal survival in specific brain regions (e.g., hippocampus, cortex) using techniques like Nissl staining or immunohistochemistry for neuronal markers, and assessment of neurological deficit scores (e.g., Bederson or Garcia scales) to gauge functional recovery. These studies aim to understand the optimal timing and dosing strategies for Cerebrolysin in an acute ischemic context within controlled experimental settings, without making any implications for human clinical use.
Beyond acute neuroprotection, researchers are also exploring Cerebrolysin’s potential role in promoting neurorestoration and recovery in the subacute and chronic phases following ischemia in experimental animals. This includes investigations into its effects on angiogenesis (formation of new blood vessels), neurogenesis (birth of new neurons, particularly in the subventricular zone and subgranular zone), and synaptic plasticity within the peri-infarct region. Studies often employ advanced imaging techniques, progenitor cell labeling, and electrophysiological recordings to monitor these regenerative processes. The hypothesis is that Cerebrolysin’s multifaceted neurotrophic and neuromodulatory properties could contribute to long-term functional improvements by supporting brain repair mechanisms, making it a compelling agent for studying recovery pathways in post-ischemic models.
The mechanisms underlying Cerebrolysin’s observed effects in ischemia models are proposed to involve its influence on energy metabolism, excitotoxicity, inflammation, and neurotrophic factor signaling, as discussed in previous sections. For instance, by potentially stabilizing mitochondria and reducing oxidative stress, it could mitigate the immediate cellular damage caused by reperfusion injury. By modulating inflammatory responses, it could limit secondary damage and create a more conducive environment for repair. The interaction of these various mechanisms highlights the complex nature of Cerebrolysin as a research tool, allowing investigators to probe the interplay of multiple pathological processes and potential interventions in cerebral ischemia models. Rigorous adherence to standardized experimental protocols, coupled with careful interpretation of findings within the research-use-only framework, is essential for advancing our understanding of Cerebrolysin’s comparative pharmacology in this critical area.
Considerations for Cerebrolysin Research Design and Interpretation
Designing robust research studies involving Cerebrolysin requires meticulous attention to experimental methodology to ensure the validity, reproducibility, and interpretability of findings. Given its complex, porcine-derived composition, specific considerations are paramount from a regulatory and compliance perspective for research-use-only applications. One critical aspect is the characterization and consistency of the Cerebrolysin preparation itself. Researchers must ensure that the lot-to-lot variability is minimized, and comprehensive analytical data, such as a Certificate of Analysis (CoA), are available for each batch. This documentation is vital for confirming the identity, purity, and concentration of the preparation, enabling researchers to attribute observed effects accurately to the compound under investigation and not to extraneous factors.
Furthermore, the selection and validation of appropriate experimental models are crucial. Whether employing in vitro cellular assays, organotypic slice cultures, or in vivo animal models, researchers must justify their model choice based on its relevance to the specific neurobiological question being addressed. Considerations such as species-specific responses, age of animals, gender differences, and underlying
Frequently Asked Questions
What is Cerebrolysin’s primary classification in research?
Cerebrolysin is classified as a neuropeptide preparation in research, deriving from porcine brain tissue and containing a complex mixture of low-molecular-weight peptides and amino acids. It is investigated for its potential neurotrophic properties in various experimental models.
How does Cerebrolysin’s proposed mechanism of action compare to NGF or BDNF in research models?
While Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) are specific, singular neurotrophic proteins, Cerebrolysin is a mixture of peptides. Research suggests Cerebrolysin may exhibit neurotrophic-like effects by modulating multiple pathways, potentially including aspects of NGF and BDNF signaling, rather than acting as a single, direct ligand.
What research models have been employed to study Cerebrolysin’s neurotrophic properties?
Research into Cerebrolysin’s neurotrophic properties has utilized a range of in vitro models, such as neuronal cell cultures exposed to various stressors, and in vivo animal models, including those simulating cerebral ischemia, traumatic brain injury, and neurodegenerative conditions.
Are there research studies comparing Cerebrolysin’s effects on synaptic plasticity with synthetic nootropics?
Yes, some research studies explore Cerebrolysin’s potential to influence synaptic plasticity in experimental models, and these investigations may involve comparisons with synthetic nootropics to understand differential or complementary effects on learning and memory-related pathways in laboratory settings.
What considerations are important when designing comparative studies involving Cerebrolysin?
When designing comparative studies with Cerebrolysin, important considerations include the specific research question, the choice of comparator compound (e.g., other neuropeptides, small molecules, or established neurotrophic factors), the experimental model, outcome measures, and appropriate control groups to ensure robust and interpretable results.
How does Cerebrolysin differ from single-peptide preparations in research contexts?
Cerebrolysin’s primary distinction from single-peptide preparations lies in its complex, multi-component nature. While a single-peptide preparation focuses on one specific biological target or pathway, Cerebrolysin’s mixture of peptides is hypothesized to exert pleiotropic effects on multiple cellular processes, which is a key area of ongoing research.
Have animal models exploring Cerebrolysin’s influence on neurogenesis been compared with other compounds?
Research has investigated Cerebrolysin’s potential impact on neurogenesis in various animal models, with some studies performing comparisons to other compounds known or hypothesized to influence neurogenic processes. Such comparative research aims to elucidate distinct mechanisms or potencies in experimental settings.
What research methodologies are commonly used to investigate Cerebrolysin’s impact on neuronal survival?
Common research methodologies for investigating Cerebrolysin’s impact on neuronal survival include in vitro assays on primary neuronal cultures or immortalized cell lines under stress conditions (e.g., excitotoxicity, oxidative stress), and in vivo studies using histological staining, Western blotting, and behavioral assessments in relevant animal models.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.